TCPG
VKTX icon

Trivant Custom Portfolio Group’s Viking Therapeutics VKTX Stock Holding History

Trivant Custom Portfolio Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$242 – 207
2025
Q1 		$242 Buy
+10
New +$316 ﹤0.01% 192

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Trivant Custom Portfolio Group's VKTX Position: Q2 2025 in Review

Trivant Custom Portfolio Group sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 10 shares — an estimated $242 sold.

Trivant Custom Portfolio Group first reported a position in VKTX in Q1 2025 and held it in 1 quarter. The position peaked at $242 in Q1 2025. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Trivant Custom Portfolio Group reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 10 Viking Therapeutics shares in Q2 2025, an estimated $242.
  • Trivant Custom Portfolio Group first reported a position in Viking Therapeutics in Q1 2025 and held it in 1 quarter.
  • Trivant Custom Portfolio Group's Viking Therapeutics position peaked at $242 in Q1 2025.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2025, filed 12 Aug 2025.